Back

Medscape, LLC

  • Melanoma

Clinical Quiz: Patient Eligibility and Clinical Trial Enrollment for LAG3 Inhibitors in Melanoma

The goal of this activity is for learners to be better able to evaluate patient eligibility for LAG3 inhibitors in melanoma treatment and understand the clinical trial criteria for enrolling patients in studies involving these therapies.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.25 credits

MOC types

ABIM — Medical KnowledgeUp to 0.25 points

FDA REMS

No

Qualifies for MIPS

No

Faculty 1

All faculty
  • Omid Hamid, MD

    Chief, Translational Research and Immuno-Oncology, The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.25 credits
  • MOC · Up to 0.25 points
  • Commercial Support
  • Released
    Dec 5, 2025
  • Last day to claim credit
    Dec 6, 2026 8 weeks left